BLUE
bluebird bio, Inc. [BLUE] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
BLUE Stock Summary
Top 10 Correlated ETFs
BLUE
Top 10 Correlated Stocks
BLUE
In the News
Are Gene Therapy Stocks The Market's Next Big Winners?
It's not often that you see a company whose main product comes with a price tag of over $2 million, but that's the case with biotechs BioMarin Pharmaceutical NASDAQ: BMRN and Sarepta Therapeutics NASDAQ: SRPT, which are developing gene therapies. ‘
Better Growth Stock: CRISPR Therapeutics vs. Bluebird Bio
CRISPR Therapeutics and Bluebird Bio each have potential growth catalysts coming in the next 12 months. CRISPR Therapeutics has a powerful ally and plenty of cash.
2 Growth Stocks That Could Rocket 88% to 99% Higher According to Wall Street
The consensus price target for Recursion Pharmaceuticals suggests the stock can soar 88% from recent prices. The average analyst estimates for bluebird bio stock imply a gain of 99% over the next 12 months.
Is Bluebird Bio a Bargain Buy in September?
Bluebird Bio is strapped for cash, and a lot of must-do spending is coming up. It will likely need to scale up its clinic footprint while also launching a new medicine.
August MDA Breakout Stocks Week 35 - 2023: High-Frequency Gainers To Give You An Edge
Two new sample Breakout Stocks for Week 35 curated by the MDA model for a 10% short-term upside along with a Dow pick. The Momentum Gauges, S&P 500 Gauges, and Weekly Gauges all continue negative after the longest positive signal since March 2021 on the weekly gauges. Last week three of the four picks gained over the 10% mark, closing up an average of +9.17% for the week with strong Segment 6 momentum.
1 Beaten-Down Growth Stock You'd Regret Not Buying on the Dip, According to Wall Street
Bluebird Bio has two approved gene-editing treatments, but they aren't generating much sales yet. The small-cap biotech company could earn another approval by the end of the year.
7 Very Oversold Nasdaq Stocks to Buy Right Now
The Nasdaq has taken a rather large hit in recent weeks, sinking about 7.5% between July 18 and Aug 17. Two of the main reasons for the decline are worries about U.S. inflation and the Chinese economy.
bluebird's (BLUE) Lovo-cel to Not Face Advisory Committee
bluebird (BLUE) announces that its gene therapy, lovotibeglogene autotemcel, developed for sickle cell disease, will not be scheduled for advisory committee meeting, thereby accelerating the path for approval.
bluebird (BLUE) Q2 Earnings Top, Zynteglo & Skysona Fuel Revenues
bluebird bio (BLUE) reports better-than-expected results in the second quarter of 2023 due to product revenues now being generated from Skysona (elivaldogene autotemcel) and Zynteglo (betibeglogene autotemcel).
Bluebird Bio (BLUE) Reports Q2 Loss, Misses Revenue Estimates
Bluebird Bio (BLUE) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $1.29 per share a year ago.
BLUE Financial details
BLUE Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 1.05 | 0.81 | 4.03 | 0.05 | 0.05 | |
| Net income per share | -10.68 | -14.31 | -9.95 | -8.16 | -3.39 | |
| Operating cash flow per share | -7.95 | -10.23 | -7.56 | -9.22 | -4.49 | |
| Free cash flow per share | -9.02 | -11.61 | -8.03 | -9.56 | -4.66 | |
| Cash per share | 26.62 | 20.05 | 18.52 | 4.35 | 2.29 | |
| Book value per share | 36.23 | 23.28 | 21.79 | 5.43 | 2.5 | |
| Tangible book value per share | 35.72 | 22.79 | 21.42 | 5.35 | 2.36 | |
| Share holders equity per share | 36.23 | 23.28 | 21.79 | 5.43 | 2.5 | |
| Interest debt per share | 3.26 | 4.09 | 3.1 | 1.3 | 3.32 | |
| Market cap | 3.34B | 3.14B | 1.74B | 688.41M | 543.81M | |
| Enterprise value | 3.1B | 3B | 1.62B | 616.83M | 712.19M | |
| P/E ratio | -6.02 | -3.97 | -2.82 | -1.22 | -2.04 | |
| Price to sales ratio | 61.25 | 70.21 | 6.95 | 187.99 | 151.18 | |
| POCF ratio | -8.09 | -5.56 | -3.7 | -1.08 | -1.54 | |
| PFCF ratio | -7.13 | -4.9 | -3.49 | -1.05 | -1.49 | |
| P/B Ratio | 1.77 | 2.44 | 1.29 | 1.84 | 2.77 | |
| PTB ratio | 1.77 | 2.44 | 1.29 | 1.84 | 2.77 | |
| EV to sales | 56.71 | 67.16 | 6.45 | 168.44 | 198 | |
| Enterprise value over EBITDA | -5.47 | -3.71 | -2.54 | -1.14 | -2.57 | |
| EV to operating cash flow | -7.49 | -5.32 | -3.44 | -0.97 | -2.02 | |
| EV to free cash flow | -6.6 | -4.68 | -3.24 | -0.94 | -1.95 | |
| Earnings yield | -0.17 | -0.25 | -0.36 | -0.82 | -0.49 | |
| Free cash flow yield | -0.14 | -0.2 | -0.29 | -0.96 | -0.67 | |
| Debt to equity | 0.08 | 0.15 | 0.14 | 0.24 | 1.43 | |
| Debt to assets | 0.07 | 0.11 | 0.11 | 0.15 | 0.51 | |
| Net debt to EBITDA | 0.44 | 0.17 | 0.2 | 0.13 | -0.61 | |
| Current ratio | 9.69 | 5.15 | 5.97 | 2.2 | 1.56 | |
| Interest coverage | -39.12 | -23.36 | 0 | 0 | 13.92 | |
| Income quality | 0.74 | 0.71 | 0.76 | 0.78 | 1.32 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 3.19 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 8.22 | 13.04 | 2.34 | 87.37 | 66.93 | |
| Intangibles to total assets | 0.01 | 0.02 | 0.01 | 0.01 | 0.02 | |
| Capex to operating cash flow | 0.13 | 0.14 | 0.06 | 0.04 | 0.04 | |
| Capex to revenue | -1.02 | -1.71 | -0.12 | -6.28 | -3.67 | |
| Capex to depreciation | -3.25 | -4.37 | -1.5 | -1.17 | -2.64 | |
| Stock based compensation to revenue | 2.03 | 3.6 | 0.62 | 34.93 | 9.78 | |
| Graham number | 93.3 | 86.57 | 69.85 | 31.59 | 13.81 | |
| ROIC | -0.26 | -0.49 | -0.36 | -1.07 | -0.38 | |
| Return on tangible assets | -0.25 | -0.46 | -0.35 | -0.96 | -0.49 | |
| Graham Net | 15.09 | 10.9 | 10.78 | 0.5 | -2.17 | |
| Working capital | 1.27B | 928.59M | 1.01B | 183.53M | 71.25M | |
| Tangible asset value | 1.86B | 1.26B | 1.33B | 368.63M | 185.83M | |
| Net current asset value | 1.06B | 709.74M | 789.34M | 117M | -159.07M | |
| Invested capital | 0.08 | 0.15 | 0.14 | 0.24 | 1.43 | |
| Average receivables | 8.52M | 13.38M | 19.82M | 19.1M | 11.09M | |
| Average payables | 15.35M | 30.41M | 32.3M | 23.74M | 25.49M | |
| Average inventory | -258.81M | -325.23M | -147.02M | -129.1M | -54.96M | |
| Days sales outstanding | 93.16 | 104.79 | 39.03 | 1.14K | 1.09K | |
| Days payables outstanding | 7.35K | 5.27K | 1.46K | 243.13 | 908.86 | |
| Days of inventory on hand | -208.74K | -17.69K | -10.13K | -1.02K | -51.22 | |
| Receivables turnover | 3.92 | 3.48 | 9.35 | 0.32 | 0.33 | |
| Payables turnover | 0.05 | 0.07 | 0.25 | 1.5 | 0.4 | |
| Inventory turnover | 0 | -0.02 | -0.04 | -0.36 | -7.13 | |
| ROE | -0.29 | -0.61 | -0.46 | -1.5 | -1.36 | |
| Capex per share | -1.07 | -1.38 | -0.47 | -0.33 | -0.17 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
| Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.02 | 0 | 0 | 0.02 | 0.06 | |
| Net income per share | -1.26 | -0.94 | 0.38 | 0.33 | -0.67 | |
| Operating cash flow per share | -1.28 | -0.94 | -0.66 | -0.84 | -0.67 | |
| Free cash flow per share | -1.36 | -0.96 | -0.72 | -0.85 | -0.68 | |
| Cash per share | 1.8 | 1.71 | 2.12 | 3.09 | 2.26 | |
| Book value per share | 2.44 | 1.95 | 2.3 | 3.45 | 2.66 | |
| Tangible book value per share | 2.39 | 1.88 | 2.18 | 3.34 | 2.56 | |
| Share holders equity per share | 2.44 | 1.95 | 2.3 | 3.45 | 2.66 | |
| Interest debt per share | 3.97 | 3.42 | 3.3 | 1.74 | 2.82 | |
| Market cap | 305.4M | 516.17M | 589.46M | 327.29M | 357.57M | |
| Enterprise value | 516.86M | 727.9M | 757.84M | 361.62M | 491.56M | |
| P/E ratio | -0.82 | -1.69 | 4.57 | 2.4 | -1.23 | |
| Price to sales ratio | 201.05 | 7.27K | 9.51K | 137.46 | 51.9 | |
| POCF ratio | -3.24 | -6.7 | -10.47 | -3.78 | -4.92 | |
| PFCF ratio | -3.04 | -6.59 | -9.6 | -3.73 | -4.87 | |
| P/B Ratio | 1.7 | 3.25 | 3 | 0.92 | 1.24 | |
| PTB ratio | 1.7 | 3.25 | 3 | 0.92 | 1.24 | |
| EV to sales | 340.27 | 10.25K | 12.22K | 151.88 | 71.34 | |
| Enterprise value over EBITDA | -5.57 | -8.25 | 29.8 | -4.28 | -5.83 | |
| EV to operating cash flow | -5.48 | -9.45 | -13.47 | -4.17 | -6.76 | |
| EV to free cash flow | -5.15 | -9.3 | -12.35 | -4.12 | -6.69 | |
| Earnings yield | -0.3 | -0.15 | 0.05 | 0.1 | -0.2 | |
| Free cash flow yield | -0.33 | -0.15 | -0.1 | -0.27 | -0.21 | |
| Debt to equity | 1.63 | 1.75 | 1.43 | 0.77 | 1.06 | |
| Debt to assets | 0.51 | 0.53 | 0.51 | 0.39 | 0.46 | |
| Net debt to EBITDA | -2.28 | -2.4 | 6.62 | -0.41 | -1.59 | |
| Current ratio | 1.12 | 1.27 | 1.56 | 3.03 | 2.13 | |
| Interest coverage | -617.24 | -225.8 | -2.06K | -0.09 | 0 | |
| Income quality | 0.94 | 1.01 | -1.75 | -4.08 | 1 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 42.03 | 748.58 | 740.31 | 19.38 | 6.14 | |
| Intangibles to total assets | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | |
| Capex to operating cash flow | 0.06 | 0.02 | 0.09 | 0.01 | 0.01 | |
| Capex to revenue | -3.94 | -17.8 | -82.39 | -0.46 | -0.1 | |
| Capex to depreciation | -4.45 | -0.91 | -4.07 | -1.02 | -0.73 | |
| Stock based compensation to revenue | 5.86 | 129.73 | 75.47 | 2.26 | 0.84 | |
| Graham number | 8.32 | 6.41 | 4.43 | 5.06 | 6.34 | |
| ROIC | -0.13 | -0.12 | 0.03 | 0.02 | -0.09 | |
| Return on tangible assets | -0.16 | -0.15 | 0.06 | 0.05 | -0.11 | |
| Graham Net | -3.33 | -2.56 | -2.01 | -0.06 | -1.02 | |
| Working capital | 18.6M | 33.71M | 71.25M | 235.14M | 152.96M | |
| Tangible asset value | 174.47M | 153.21M | 185.83M | 343.48M | 277.88M | |
| Net current asset value | -226.02M | -200.8M | -159.07M | 13.08M | -86.4M | |
| Invested capital | 1.63 | 1.75 | 1.43 | 0.77 | 1.06 | |
| Average receivables | 11M | 11.51M | 11.66M | 13.16M | 15.49M | |
| Average payables | 26.61M | 21.74M | 21.86M | 22.16M | 15.06M | |
| Average inventory | 7.54M | 11.3M | 3.05M | 1.2M | 8.73M | |
| Days sales outstanding | 620.7 | 15.89K | 15.66K | 587.36 | 201.62 | |
| Days payables outstanding | 1.28K | 0 | 102.65K | 512.78 | 102.52 | |
| Days of inventory on hand | 777.97 | 0 | -5.78K | 101.54 | 128.38 | |
| Receivables turnover | 0.14 | 0.01 | 0.01 | 0.15 | 0.45 | |
| Payables turnover | 0.07 | 0 | 0 | 0.18 | 0.88 | |
| Inventory turnover | 0.12 | 0 | -0.02 | 0.89 | 0.7 | |
| ROE | -0.52 | -0.48 | 0.16 | 0.1 | -0.25 | |
| Capex per share | -0.08 | -0.02 | -0.06 | -0.01 | -0.01 |
BLUE Frequently Asked Questions
What is bluebird bio, Inc. stock symbol ?
bluebird bio, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol BLUE
Is bluebird bio, Inc. buy or a sell ?
8 stock analysts have 8 predictions with a medium analyst target price of $14.13. The lowest prediction is $5 and the highest is $25
What is BLUE stock prediction ?
What is bluebird bio, Inc. stock quote today ?
bluebird bio, Inc. stock price is $3.02 today.
Is bluebird bio, Inc. stock public?
Yes, bluebird bio, Inc. is a publicly traded company.
Company Profile
- Volume Average 4.2M
- Market Capitalization 325.14M
- Employee 323
- CEO Mr. Andrew Obenshain
- Headquarters Cambridge,MA,US
- IPO Date 2013-06-19
-
Website
https://www.bluebirdbio.com 
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
